- Home
- ALEC vs ACRS Comparison
ALEC vs ACRS Comparison
Compare ALEC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | ACRS |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.2M | 311.0M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALEC | ACRS |
|---|---|---|
| Price | $2.18 | $4.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.83 | ★ $10.20 |
| AVG Volume (30 Days) | 437.9K | ★ 1.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,045,000.00 | $1,683,000.00 |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $29.87 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $1.22 |
| 52 Week High | $3.40 | $5.12 |
Technical Indicators
Market Signals| Indicator | ALEC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 67.33 |
| Support Level | $1.89 | $2.67 |
| Resistance Level | $2.57 | N/A |
| Average True Range (ATR) | 0.16 | 0.26 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 24.46 | 79.81 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.